Imviva Biotech will present data from its allogeneic CAR‑T programs at the 67th ASH Annual Meeting in Orlando (Dec 6–9, 2025), including two oral talks and five poster sessions. The company will spotlight CTD402 (its lead investigational product) and CTA311, targeted at disorders such as severe aplastic anemia and acute lymphoblastic leukemia. Imviva’s CMO Jan Davidson‑Moncada emphasized the ANSWER platform’s potential and reported breakthrough progress for CTD402.
Imviva Biotech to Reveal Breakthrough Allogeneic CAR‑T Data for Leukemia and Aplastic Anemia at ASH 2025
09:13 AM, 11/25/2025Health
Similar Articles
Eli Lilly Secures Global Rights to MeiraGTx’s AAV‑AIPL1 Gene Therapy in Deal Worth Up to $475M
MeiraGTx has granted Eli Lilly worldwide rights to its experimental AAV-AIPL1 gene therapy in a deal that could exceed $475 m...
Reprogramming the Immune System: New Frontiers in Treating Autoimmune Diseases
Scientists are shifting from suppressing the immune system to reprogramming it —using CAR-T, regulatory T cells, T cell-engag...
Linker Breakthroughs at CPHI 2025 Unlock Greater Stability and New Payloads for ADCs
At CPHI 2025, experts reported that innovations in linker chemistry are enabling more stable and selective ADCs and expanding...
Chiesi Secures Exclusive Licence from Aliada for Blood–Brain Barrier‑Crossing Enzyme Replacement Therapies
Chiesi has secured an exclusive worldwide licence from Aliada Therapeutics (an AbbVie unit) to develop enzyme replacement the...
Avant and SGAustria Launch Insulinova JV to Advance Encapsulated Stem‑Cell Diabetes Therapy
Avant Technologies and SGAustria have created a US‑based joint venture, Insulinova, to develop diabetes treatments that combi...
Two FDA-Approved Cancer Drugs, Combined, Reduce a Key Alzheimer’s Protein in Mice — 1.4M Health Records Helped Point the Way
UCSF researchers used gene-expression screening and 1.4 million anonymized health records to repurpose existing drugs for Alz...
UCLA Engineers Off‑the‑Shelf CAR‑NKT Cells That Hunt and Destroy Pancreatic Tumors in Mice
UCLA researchers engineered off‑the‑shelf CAR‑modified invariant NKT cells from donated stem cells that penetrated solid panc...
FDA’s Proposed Gene‑Therapy Pathway Could Accelerate Bespoke Treatments — Key Questions Remain
Summary: The FDA has proposed a pathway that could speed personalised gene therapies when a clear molecular defect is targete...
Respiratory Cell & Gene Therapy: Why Progress Lags — and What Could Change Next
Key points: Venture funding for CGTs dropped from $35.9bn in 2021 to $23.3bn in 2024, driven by trial failures and manufactur...
AHA 2025: AAV‑delivered BacNav Gene Therapy Restores Contractility and Prevents Arrhythmia in Preclinical Heart‑Failure Models
At AHA 2025, researchers reported that AAV9‑delivered BacNav, a prokaryotic voltage‑gated sodium channel gene, improved cardi...
Breakthrough at Tel Aviv University: Gene Therapy Restores Hearing and Balance in Mice
Key points: Tel Aviv University researchers used a self‑complementary AAV (scAAV) vector to restore balance in nearly 100% of...
Nanotech Remodels Chemo Drug to Target Leukemia — ~20,000× Potency Gain in Mice, Human Trials Planned
Researchers at Northwestern University embedded 5-fluorouracil (5FU) into spherical nucleic acids, converting the drug from a linear to a globular form that improved solubilit...
Inside the Labs Unraveling Autoimmune Disease: How Scientists Hunt Rogue Immune Cells
Leading labs at the NIH and Johns Hopkins are using advanced imaging and molecular tools to pinpoint what triggers autoimmune...
5 Biology Breakthroughs That Could Transform Medicine, Conservation and Research
Researchers reported five notable biological advances this year: a gene therapy that can slow Huntington's disease by about 7...
“Disease of 1,000 Faces”: How Researchers Are Unraveling Autoimmunity and Changing Care
Ruth Wilson’s six-year struggle to get a lupus diagnosis highlights the hidden toll of autoimmune diseases, which affect tens...
Matisse Reports Positive Phase I Results for 120‑Hour M6229 IV Infusion, Clearing Path for Phase II Sepsis Study
Matisse Pharmaceuticals reported positive Phase I top-line results from a randomized, placebo-controlled, single-blind study ...
Biotechs in Próspera Pursue Combination Gene‑Therapies to Tackle Ageing
Próspera, a Honduran charter city on Roatán island, has drawn longevity startups by offering a permissive regulatory environm...
Beyond CHO: New Protein‑Manufacturing Platforms Poised to Transform Complex Biologics in 5–10 Years
Overview: While CHO cells remain the dominant platform for large‑molecule production, their limitations are blocking scale‑up...
FDA Places Clinical Hold on Tenaya’s TN-201 Gene Therapy Trial for Rare Inherited Heart Disease
Key points: The U.S. FDA has placed a clinical hold on Tenaya Therapeutics’ TN-201 gene therapy trial for hypertrophic cardio...
New “Brainshuttle” Trial in Hawaii Shows Faster, Safer Delivery of Alzheimer’s Drugs
The Memory & Alzheimer’s Research Center in Hawaii is testing a “Brainshuttle” antibody fragment to ferry Alzheimer’s dru...